Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin microspheres for ovarian protection during adjuvant chemotherapy in premenopausal early-stage breast cancer
ChiCTR2500112908Phase 2Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Nov 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of goserelin in breast cancer, sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: AMH recovery rate at 12 months after chemotherapy. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500112908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112908.